Tuloy na ang stem cell therapy ni Annabelle Rama dahil naka-schedule na siyang pumunta sa Germany sa first week ng September. Kasama ni Annabelle sa Germany trip ang kanyang anak na si Ruffa Gutierrez. Hindi ako sure kung may plano rin si Ruffa na magpa-stem cell therapy dahil walang age limit ang procedure na pinag-uusapan na ngayon sa apat na sulok ng showbiz. Tinutukso si Annabelle Rama na may kinalaman sa kanyang pagkandidato sa Cebu ang desisyon niya na sumailalim sa stem cell therapy. Tumawa lang si Bisaya na mukhang seryoso na sa pagkandidato bilang kongresista ng North Cebu sa eleksiyon sa susunod na taon. Binibiro si Bisaya na magpapa-stem cell therapy siya para kundisyon na kundisyon ang katawan niya habang nangangampanya sa North Cebu. Ayaw kumpirmahin ni Bisaya ang political plans niya. Hintayin na lamang daw ng mga tao ang kanyang bonggang announcement sa October. Asawa ni Jose nag-iba ng abogado matapos matalo How true na iba na raw ang lawyers ni Analyn Manalo kaya tumanggi nang magsalita ang kanyang mga dating abogado? Si Analyn ang kontrobersiyal na dyowa ni Jose Manalo. Ilang buwan nang nasa news ang mag-asawa dahil sa kanilang paghihiwalay. News noong weekend na natalo si … Continue reading →

Spencer Platt/Getty Images A scientist holds a tray of stem cells. Federal authorities have given the go-ahead to human trials that will use a new stem cell treatment to repair heart attack damage. Researchers at Cedars-Sinai in Los Angeles led the study into this new stem-cell-based treatment that helps to repair damage that cardiac arrest inflicts on heart muscle. While preliminary therapies derived from a patients own cells have shown to reduce heart attack scarring, this new therapy would treat victims with human stem cells that are mass-replicated in a lab. Research into the new therapy was supported by a $5.5 million grant from CIRM the California stem cell agency that was created by voter-approved Proposition 71. This success marks the first time research by a CIRM-funded disease team has resulted in the FDA approving a potential new drug for clinical trials in humans. Researchers say that, if its ultimately approved by the FDA, the new therapy could help the hundreds of thousands of Americans who each year have heart attacks. View original post here: FDA approves clinical trials for new stem cell therapy for heart attack patients … Continue reading →

The days of "stem-cell tourism" could be numbered. Six residents of Los Angeles, California, are suing South Korean company RNL Bio and associates in a Californian court for alleged fraud. They claim the company convinced them to travel to clinics in South Korea, China or Mexico to donate fat tissue and have stem cells from it re-administered to cure diseases and even reverse ageing. Stem cells hold great medical promise, but only one treatment is licensed in the US and that is for a rare blood disorder. Others are experimental and it is illegal to offer them commercially. Yet some companies still tout stem-cell "cures" that are carried out outside the US. RNL Bio calls its fat-tissue stem cells "safe technologies" for treating various disorders. There have been protests against these treatments for years, but this is the first civil lawsuit for damages, says Paul Knoepfler of the University of California at Davis. It "serves notice to the purveyors of unproven stem-cell treatments" that they may face litigation if they market in the US, says Bernard Siegel of the Genetics Policy Institute, a stem-cell watchdog in Palm Beach, Florida. If you would like to reuse any content from New Scientist, … Continue reading →

Mesoblast (MSB.AX) (OTC:MEOBF) CEO Silviu Itesu speaks on his company`s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that the technology implies. Itesu discusses development compound Revascor for use in congestive heart failure and details the latest Phase II results. In 60 patients the drug saw no adverse events and a 0% event rate (hospital visits, mortality) compared to 20% in a control group; the company is planning to initiate a 1500-patient Phase III study in the coming few months. The trials are funded entirely by Teva (TEVA), says Itesu, but the company`s financial situation would allow for a few years of `solo` operation. Itesu briefly compares Mesoblast`s production strategies to those of Dendreon`s (DNDN) Provenge, and explains how Mesoblast`s production will be significantly less expensive. The conversation also covers two more pipeline products, a Type-2 diabetes treatment and an intervertebral disc treatment, both of which have shown promising results in Phase II studies. Click Here to view our video interview of Mesoblast CEO Silviu Itesu. About PropThink PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and … Continue reading →

Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Transplants / Organ Donations Article Date: 11 Jul 2012 - 0:00 PDT Current ratings for: Stem Cell Transplant Recipients - Rabbit Antibodies Help Leukemia Patients During the study, led by Amir Toor, M.D., hematologist-oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics program at VCU Massey Cancer Center, researchers viewed the outcomes of 48 patients who received a transplant of stem cells from a related donor to the outcomes of 50 patients who alternatively received rabbit anti-thymocyte globulin (ATG) before being given a transplant of stem cells from an unrelated donor. This study has been published in Bone Marrow Transplantation The results showed similar outcomes for both groups in terms of relapse, mortality, and development of graft-versus-host disease (GVHD), a common occurrence that can happen when a transplant is inserted and the new material clashes with the recipient's body. When the patients were followed up at 35 months, 50% of the ATG group and 63% of the no ATG group were still alive. Generally, unrelated stem cell transplants typically have significantly poorer outcomes. Toor says: Thus, being able to provide improved outcomes … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/t2whtl/stem_cell_research) has announced the addition of the "Stem Cell Research in India 2012" report to their offering. The stem cell research in India is in its nascent stage and is gradually on a growth path of acceptance by people. The market is still in a phase of conducting research to establish itself as one of the best therapies for the widely prevalent incurable lifestyle diseases. Awareness campaigns and doctors are playing a key role educating people and especially would-be parents about the benefits associated with preserving stem cells. The report begins with the introduction section which offers a brief insight of the concept of stem cell therapy and banking, the conventional sources of stem cells and the current and future therapeutic solutions for the most risky diseases. It then moves to the market overview section which provides an insight of the Indian stem cell therapy market, with highlight on the market size and growth. It also covers the market size and growth prospect of the stem cell banking market in India. In addition to these, the report gives a snapshot of the current and expected stem cell banking customers. An analysis of the drivers explains … Continue reading →

DULUTH, Ga., July 11, 2012 /PRNewswire/ -- ChildCare Education Institute (CCEI), an IACET approved, nationally accredited, online training institution dedicated exclusively to the child care and education workforce, is proud to announce the addition of SPN103: Teaching Young Children with Autism Spectrum Disorder to the online child care training course catalog. (Logo: http://photos.prnewswire.com/prnh/20111019/MM90221LOGO) Despite the growing diagnoses of Autism Spectrum Disorder (ASD), there are still many misconceptions, including that children with ASD cannot be successfully included in group settings. CCEI's course Teaching Young Children with Autism Spectrum Disorder presents recommended practices and activities for welcoming a child with autism spectrum disorder into the group preschool setting. Included in the course is guidance for designing and implementing a developmentally appropriate, safe, effective program, including strategies for readying the child and his or her family for the new environment. The course also includes strategies for preparing the classroom, transitions between activities, and helping children with autism feel a sense of value and belonging. This course was authored by Clarissa Willis, and is excerpted from her book, Teaching Young Children with Autism Spectrum Disorder. "Recent data on ASD diagnosis rates shows clearly that early childhood educators need to be prepared to welcome young … Continue reading →